A role for hepatic metastasectomy in stage IV melanoma and breast cancer: Reestablishing the surgical modality

Oncology

Volumn 25, Issue 12, 2011, Pages

  Zani, Sabino ^a   Clary, Bryan M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; MELPHALAN; PACLITAXEL; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB; VEMURAFENIB;

ARTIFICIAL EMBOLISM; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL (TOPIC); DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; LIVER METASTASIS; LIVER RESECTION; MEDICAL LITERATURE; MELANOMA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME; UVEA MELANOMA;

EID: 80855135546     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin. 1999;49:231-55.
2. Fuhrman GM, Curley SA, Hohn DC, Roh MS. Improved survival after resection of colorectal liver metastases. Ann Surg Oncol. 1995;2:537-41.
3. Adam R, Pascal G, Azoulay D, et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238:871-83; discussion 83-4.
4. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-45.
5. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38-46.
6. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-66.
7. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest. 2009;27:682-90.
8. Wolchok JD, Thomas L, et al. Phase III randomized study of ipilimumab plus dacarbazine vs DTIC alone as first-line treatment in patient with unresectable stage III or IV melanoma. ASCO Annual Meeting. 2011;Abstract LBA5.
9. Chapman PB, Robert C, et al. Phase III randomized, open-label multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma. ASCO Annual Meeting. 2011;Abstract LBA4.
10. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
11. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5-24.
12. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823-30.
13. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-26.
14. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589-95.
15. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465-74.
16. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:956-61.
17. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87:840-5.
18. Leiter U, Meier F, Schittek B Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172-8.
19. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, et al. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncologica. 1999;38:549-57.
20. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg. 1990;212:173-7.
21. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334-6.
22. Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:8076-80.
23. Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136:950-5.
24. Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524-35.
25. Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712-20.
26. Rivoire M, Kodjikian L, Baldo S, et al. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005;12:422-8.
27. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years experience at the Institut Curie. Eur J Surg Oncol. 2009;35:1192-7.
28. Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93:1042-6.
29. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol. 2002;9:762-70.
30. Hoe AL, Royle GT, Taylor I. Breast liver metastasesincidence, diagnosis and outcome. J Royal Soc Med. 1991;84:714-6.
31. Zinser JW, Hortobagyi GN, Buzdar AU, et al. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987;5:773-82.
32. Howlader N, Krapcho M, Neyman N, et al (editors). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
33. Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol. 1988;6:89-97.
34. OReilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer. 1990;26:574-7.
35. Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003;89:284-90.
36. Insa A, Lluch A, Prosper F, et al. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 1999;56:67-78.
37. Clark GM, Sledge GW, Jr., Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5:55-61.
38. Samaan NA, Buzdar AU, Aldinger KA, et al. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981;47:554-60.
39. OShaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-9.
40. Lee YT. Breast carcinoma: pattern of recurrence and metastasis after mastectomy. Am J Clin Oncol. 1984;7:443-9.
41. Chua TC, Saxena A, Liauw W, et al. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer. 2011;
42. Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897-907; discussion 07-8.
43. Elias D, Maisonnette F, Druet-Cabanac M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg. 2003;185:158-64.
44. Hoffmann K, Franz C, Hinz U, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17:1546-54.
45. Thelen A, Benckert C, Jonas S, et al. Liver resection for metastases from breast cancer. J Surgical Oncol. 2008;97:25-9.